Stockwatch: Reading The Entrails Of Biotech Vaccine Development
Expectations Remain Far Too High For A Coronavirus Vaccine From Biotech
Executive Summary
As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.